Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTAIR: Alirocumab for Thin-cap Fibroatheroma
NCT03552432Phase 4Unknown
- Sponsor
- Kobe University
- Start
- Aug 2017
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alirocumab in coronary artery disease (CAD) (2 arms), sponsored by Kobe University. Primary endpoint: Change in fibrous cap thickness at 9 months. Status: unknown.
02
Drugs
alirocumab
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03552432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552432.